Keywords: combinatorx, initiates, ph, iia, crx-401, massachusetts, usa-based

CombinatoRx initiates Ph IIa with CRx-401

Article | 20 August 2007

Print This

Massachusetts, USA-based CombinatoRx says that it has dosed the first patient in a Phase IIa proof-of-concept clinical trial in type 2 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in